FFM
VRNA

Fairmount Funds Management’s Verona Pharma VRNA Stock Holding History

Fairmount Funds Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-381,939
Closed -$8.07M – 22
2023
Q2 		$8.07M Sell
381,939
-2,745,490
-88% -$58.6M 1.14% 16
2023
Q1 		$62.8M Buy
3,127,429
+251,903
+9% +$5.44M 10.8% 3
2022
Q4 		$75.1M Buy
2,875,526
+196,544
+7% +$2.62M 11.92% 3
2022
Q3 		$27.4M Buy
2,678,982
+1,752,380
+189% +$14.8M 4.81% 9
2022
Q2 		$3.88M Hold
926,602
– – 0.89% 24
2022
Q1 		$4.62M Hold
926,602
– – 1.09% 20
2021
Q4 		$6.23M Hold
926,602
– – 2.05% 18
2021
Q3 		$5.08M Buy
926,602
+842,658
+1,004% +$4.9M 1.85% 20
2021
Q2 		$549K Hold
83,944
– – 0.23% 19
2021
Q1 		$702K Sell
83,944
-16,056
-16% -$133K 0.3% 18
2020
Q4 		$700K Hold
100,000
– – 0.25% 17
2020
Q3 		$624K Buy
+100,000
New +$691K 0.26% 17

Other funds holding VRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Fairmount Funds Management's VRNA Position: Q3 2023 in Review

Fairmount Funds Management sold out of Verona Pharma (VRNA) in Q3 2023, closing a stake of 381,939 shares — an estimated $8.07M sold.

Fairmount Funds Management first reported a position in VRNA in Q3 2020 and held it in 12 quarters. The position peaked at $75.1M in Q4 2022. 102 funds tracked by Wall St. Rank hold VRNA as of Q3 2023.

  • Fairmount Funds Management reported no remaining Verona Pharma position as of Q3 2023 after selling out during the quarter.
  • Fairmount Funds Management sold 381,939 Verona Pharma shares in Q3 2023, an estimated $8.07M.
  • Fairmount Funds Management first reported a position in Verona Pharma in Q3 2020 and held it in 12 quarters.
  • Fairmount Funds Management's Verona Pharma position peaked at $75.1M in Q4 2022.
  • 102 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2023.

Based on Fairmount Funds Management's 13F filing for Q3 2023, filed 14 Nov 2023.